Menu Search
Equities

Numinus Wellness Inc

LR23:FRA

Numinus Wellness Inc

Actions
  • Price (EUR)0.0445
  • Today's Change0.024 / 116.02%
  • Shares traded20.00k
  • 1 Year change-45.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.

  • Revenue in CAD (TTM)20.10m
  • Net income in CAD-24.36m
  • Incorporated1962
  • Employees--
  • Location
    Numinus Wellness Inc393 Laurier Ave WMONTREAL H2V 2K3CanadaCAN
  • Phone+1 (604) 329-2079
  • Fax+1 (604) 329-2079
  • Websitehttps://numinus.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NUMI:TOR since
announced		Transaction
value
MedBright AI Investments IncAnnounced20 Jun 202420 Jun 2024Announced40.00%14.28m
Data delayed at least 15 minutes, as of Nov 11 2024 20:59 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.